发现新型3-基氨基胺素作为可口使用和内活性选择性ROS1抑制剂,用于对抗抗性ROS1G2032R突变

Siming Liu1, Yuanxin Tian1, Yaqi Huang1

  • 1NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.

概括

一种新型ROS1抑制剂,SMU-037,显示出高选择性和改善的大脑透. 它有效地向抗药性突变并抑制瘤生长,